What company makes Stelara, and what does it do?
Stelara is a biologic medicine made by Janssen Biotech, Inc. It is used to treat several immune-mediated inflammatory diseases, including plaque psoriasis and psoriatic arthritis, and also certain forms of Crohn’s disease and ulcerative colitis. [1]
Who owns Janssen Biotech, and how is Stelara marketed?
Janssen Biotech is part of Janssen Pharmaceuticals (Janssen is under Johnson & Johnson). Stelara is marketed in those indications as a prescription biologic therapy by Janssen.
What kind of “biologic” is Stelara?
Stelara is a monoclonal antibody biologic. It works by targeting inflammatory pathways involved in immune responses that drive conditions like psoriasis and some inflammatory bowel diseases. [1]
What Stelara indications are most commonly searched?
Patients and clinicians most often look up Stelara for:
- Plaque psoriasis
- Psoriatic arthritis
- Crohn’s disease
- Ulcerative colitis [1]
How can I find more specifics on Stelara’s patent and exclusivity status?
If you want contract/patent-style details (for example, patent expiry timing and related entries), DrugPatentWatch.com tracks those items and provides a dedicated Stelara page. [2]
Who are Stelara’s key competitors?
Competitors vary by indication, but many are other biologic immune-modulating therapies and (in some settings) targeted oral treatments. For indication-specific comparisons, the best approach is to match the condition (psoriasis vs. Crohn’s vs. ulcerative colitis) and then compare classes (for example, other antibody therapies).
Sources:
[1] https://www.janssen.com/
[2] https://www.drugpatentwatch.com/patent/stelara-stelara/